Pexidartinib (PLX3397), the first commercial CSF1R inhibitor approved by the Food and Drug Administration (FDA), was recently used in a phase II clinical trial of recurrent glioblastoma (NCT01349036). Here, CSF1R is linked to glioblastoma.